Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 17/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001404 | 0.80 | HTR2A (0.34) | PIK3CGHTR2AHTR2CHTR2BPIK3CD | |
| SCHEMBL1000891 | 0.78 | PARP1 (0.45) | PIK3CGHTR2AHTR2CHTR2BPIK3CD | |
| SCHEMBL1001401 | 0.75 | ITGB3 (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL1002883 | 0.74 | PARP1 (0.47) | PIK3CGHTR2AHTR2CHTR2BPIK3CD | |
| SCHEMBL2026779 | 0.65 | GRM2 (0.57) | HTR2C | |
| SCHEMBL2024939 | 0.63 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CA | |
| SCHEMBL2028811 | 0.63 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CA | |
| SCHEMBL1001402 | 0.62 | BRD4 (0.32) | PIK3CGPIK3CDPIK3R1PIK3CA | |
| SCHEMBL2022463 | 0.62 | HTR2A (0.38) | HTR2AHTR2CHTR2BGBA1 | |
| SCHEMBL2025273 | 0.61 | PARP1 (0.47) | HTR2AHTR2CHTR2BGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| EP-1912940-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | PIK3CG 1990/4885HTR2A 563/4885HTR2C 692/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | PIK3CG 1990/4885HTR2A 563/4885HTR2C 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.